Amyotrophic Lateral Sclerosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

Posted on
by

Amyotrophic Lateral Sclerosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023

DelveInsight’s, “Amyotrophic Lateral Sclerosis Pipeline Insight 2023” report provides comprehensive insights about 90+ companies and 100+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Amyotrophic Lateral Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report

  • DelveInsight’s Amyotrophic Lateral Sclerosis Pipeline analysis depicts a robust space with 90+ active players working to develop 100+ pipeline treatment therapies.
  • The leading companies working in the Amyotrophic Lateral Sclerosis Market include Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.
  • Promising Amyotrophic Lateral Sclerosis Pipeline Therapies in the various stages of development include Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, AP-101, ION363, and others.
  • December 2023: MaaT Pharma announced a study of Phase 1 clinical trials for MaaT033. The purpose of this pilot study is to assess the safety and tolerability of multiple doses of MaaT033 in ALS patients and to analyze the gut microbiota composition and evolution before considering a larger randomized controlled efficacy study.
  • December 2023: QurAlis Corporation announced a study of Phase 1 clinical trials for QRL-201- Dose 8. The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS.
  • On July 2023, Biogen announced a study of phase 3 clinical trials for Tofersen. The primary objectives of Parts A and B of this study are to evaluate the safety, tolerability, and pharmacokinetics (PK) of ascending doses of tofersen in adults with ALS and a documented superoxide dismutase 1 (SOD1) mutation. The primary objective of Part C of this study is to evaluate the clinical efficacy of tofersen administered to adults with ALS and a confirmed SOD1 mutation.
  • On January 2023, Ferrer Internacional S.A. announced a study of phase 3 clinical trials for FAB122. Multicenter, multinational, double-blind, randomized (2:1), placebo-controlled Phase III study to investigate the efficacy and safety of 100 mg FAB122 once daily as oral formulation in ALS patients.

 

Request a sample and discover the recent advances in Amyotrophic Lateral Sclerosis Treatment Drugs @ Amyotrophic Lateral Sclerosis Pipeline Outlook Report

 

In the Amyotrophic Lateral Sclerosis pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Amyotrophic Lateral Sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Amyotrophic Lateral Sclerosis Overview

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease, is a rare neurological disease that affects motor neurons—those nerve cells in the brain and spinal cord that control voluntary muscle movement. Voluntary muscles are those we choose to move to produce movements like chewing, walking, and talking. The disease is progressive, meaning the symptoms get worse over time. ALS has no cure and there is no effective treatment to reverse its progression. ALS is a type of motor neuron disease.

 

Find out more about Amyotrophic Lateral Sclerosis Treatment Landscape @ Drugs for Amyotrophic Lateral Sclerosis Treatment

 

Amyotrophic Lateral Sclerosis Emerging Drugs Profile

  • Tofersen: Biogen
  • RNS60: Revalesio Corporation
  • ANX005: Annexon

 

Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment

There are approx. 90+ key companies which are developing the therapies for Amyotrophic Lateral Sclerosis. The Amyotrophic Lateral Sclerosis companies which have their Amyotrophic Lateral Sclerosis drug candidates in the most advanced stage, i.e. Preregistration include, Biogen.

 

DelveInsight’s Amyotrophic Lateral Sclerosis pipeline report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Amyotrophic Lateral Sclerosis Pipeline Therapies @ Amyotrophic Lateral Sclerosis Clinical Trials Assessment

 

Scope of the Amyotrophic Lateral Sclerosis Pipeline Report

  • Coverage- Global
  • Amyotrophic Lateral Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Amyotrophic Lateral Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Amyotrophic Lateral Sclerosis Companies– Molecular Partners, Biogen, Ionis Pharmaceuticals, Ferrer Internacional S.A., AbbVie, Calico Life Sciences LLC, Genuv Inc., Kadimastem, Corcept Therapeutics, AL-S Pharma, Rapa Therapeutics LLC, Cytokinetics, MediciNova, Retrotope, Inc., Woolsey Pharmaceuticals, Sanofi, PTC Therapeutics, Helixmith Co., Ltd., Annexon Inc., Denali Therapeutics Inc., Revalesio Corporation, Clene Nanomedicine, Ashvattha Therapeutics Inc., Apellis Pharmaceuticals Inc., Procypra Therapeutics, Knopp Biosciences, InFlectis BioScience, AI Therapeutics Inc., Cellenkos, ZZ Biotech LLC, QurAlis Corporation, Alector Inc., NeuroSense Therapeutics Ltd., Novartis Pharmaceuticals, Eledon Pharmaceuticals, and others.
  • Amyotrophic Lateral Sclerosis Therapies– Reldesemtiv, Albutein 5%, Tofersen, FAB122, sNN0029, ABBV-CLS-7262, SPG302, Dazucorilant 300 mg, AP-101, ION363, and others.

 

Dive deep into rich insights for new drugs for Amyotrophic Lateral Sclerosis Treatment, Visit @ Amyotrophic Lateral Sclerosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Amyotrophic Lateral Sclerosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Amyotrophic Lateral Sclerosis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Tofersen: Biogen
  9. Late Stage Products (Phase III)
  10. Drug Name: Company Name
  11. Drug profiles in the detailed report…..
  12. Mid Stage Products (Phase II)
  13. RNS60: Revalesio Corporation
  14. Drug profiles in the detailed report…..
  15. Early Stage Products (Phase I)
  16. Drug Name: Company Name
  17. Drug profiles in the detailed report…..
  18. Preclinical and Discovery Stage Products
  19. Drug Name: Company Name
  20. Drug profiles in the detailed report…..
  21. Inactive Products
  22. Amyotrophic Lateral Sclerosis Key Companies
  23. Amyotrophic Lateral Sclerosis Key Products
  24. Amyotrophic Lateral Sclerosis- Unmet Needs
  25. Amyotrophic Lateral Sclerosis- Market Drivers and Barriers
  26. Amyotrophic Lateral Sclerosis- Future Perspectives and Conclusion
  27. Amyotrophic Lateral Sclerosis Analyst Views
  28. Amyotrophic Lateral Sclerosis Key Companies
  29. Appendix

 

For further information on the Amyotrophic Lateral Sclerosis Pipeline Therapeutics, reach out @ Amyotrophic Lateral Sclerosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-melanoma-market